Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.
Target Price
The average target price of FATE is 5.2 and suggests 348% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell